Name: Latest research reports of GlaxoSmithKline Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: GlaxoSmithKline Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd.

NSE: GLAXO | BSE: 500660 | ISIN: INE159A01016 | Industry: Pharmaceuticals
| Mid-range Performer

2741.1000 -14.30 (-0.52%)

NSE Sep 19, 2025 15:53 PM

42.69% Gain from 52W Low

Volume: 85,057

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024

2741.10

-0.52%

Superior execution and lower RM costs drive earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Glaxo Pharma (GLXO) delivered better-than-expected 1QFY25 performance. The robust growth in key brands, young potential brands.

GlaxoSmithKline Phar.. has an average target of 2800.00 from 2 brokers.

Trendlyne Marketwatch | 19 Sep 2025, 03:58PM

Bull run fizzles out: Multibagger count in Indian equities falls

The Baseline | 18 Sep 2025, 03:38PM

From gems to gadgets: India’s $24 billion leap into global smartphone manufacturing

The Baseline | 17 Sep 2025, 06:26PM